Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CTIL-051 by AbelZeta for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
CTIL-051 is under clinical development by AbelZeta and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...